Product Description
The compelling preclinical findings of specificity, biologic effect, tolerability and pharmacologic profile in multiple animal models following intravenous administration support the advancement of INT2104 to the clinic as a promising treatment option for B-cell malignancies," says Tim Culp, PhD, VP of Research and Development. "We continue to maintain our timeline to IND with initial human data expected in 2024. (Sourced from: https://www.benzinga.com/pressreleases/23/06/n32940039/interius-biotherapeutics-highlights-strong-preclinical-data-supporting-in-vivo-chimeric-antigen-re)
Mechanisms of Action: CAR-T, CD20
Novel Mechanism: Yes
Modality: In Vivo CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Interius
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: B-Cell Leukemia|Lymphoid Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06539338 |
INVISE | P1 |
Recruiting |
Lymphoma, Non-Hodgkin|Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Lymphoma, B-Cell |
2028-03-01 |
50% |
2025-07-30 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/21/2025 |
News Article |
Viral Vectors and Plasmid DNA Manufacturing Market Size Worth USD 26.66 Billion by 2034 Driven by Gene Therapy Demand |
|
04/17/2025 |
News Article |
Interius BioTherapeutics to Present at Upcoming Scientific Meetings |
|
01/07/2025 |
News Article |
Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe |
|
10/23/2024 |
News Article |
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies |